Biomarkers of Atrial Fibrillation Complicated With Stroke Based on Proteomics and Metabolomics

Last updated: January 8, 2022
Sponsor: Yue LI
Overall Status: Active - Recruiting

Phase

N/A

Condition

Stroke

Arrhythmia

Cardiac Disease

Treatment

N/A

Clinical Study ID

NCT05181787
AF and stroke 1
  • Ages > 18
  • All Genders

Study Summary

Thrombus shedding in patients with atrial fibrillation (AF) can lead to cerebral artery embolism. Stroke caused by AF is very dangerous, which not only threatens the life of patients, but also seriously affects the quality of life. This study aims to explore the biomarkers of stroke in patients with AF by integrating proteomics and metabolomics data, and establish the network relationship of stroke in patients with AF, so as to reveal the molecular mechanism of stroke in patients with AF.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age 18 years or above
  2. Admission with atrial fibrillation or clinic visit for atrial fibrillation
  3. Receive routine anticoagulant therapy;
  4. Signing the consent form

Exclusion

Exclusion Criteria:

  1. Pregnant women;
  2. Lactating women;
  3. Severe mitral stenosis;
  4. Severe impairment of liver function;
  5. Severe renal insufficiency;
  6. Thyroid dysfunction requiring treatment.

Study Design

Total Participants: 200
Study Start date:
December 20, 2021
Estimated Completion Date:
December 31, 2023

Connect with a study center

  • Yan

    Harbin, Heilongjiang 150001
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.